Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
Mol Cell
; 79(1): 191-198.e3, 2020 07 02.
Article
em En
| MEDLINE
| ID: mdl-32619469
ABSTRACT
We recently used CRISPRi/a-based chemical-genetic screens and cell biological, biochemical, and structural assays to determine that rigosertib, an anti-cancer agent in phase III clinical trials, kills cancer cells by destabilizing microtubules. Reddy and co-workers (Baker et al., 2020, this issue of Molecular Cell) suggest that a contaminating degradation product in commercial formulations of rigosertib is responsible for the microtubule-destabilizing activity. Here, we demonstrate that cells treated with pharmaceutical-grade rigosertib (>99.9% purity) or commercially obtained rigosertib have qualitatively indistinguishable phenotypes across multiple assays. The two formulations have indistinguishable chemical-genetic interactions with genes that modulate microtubule stability, both destabilize microtubules in cells and in vitro, and expression of a rationally designed tubulin mutant with a mutation in the rigosertib binding site (L240F TUBB) allows cells to proliferate in the presence of either formulation. Importantly, the specificity of the L240F TUBB mutant for microtubule-destabilizing agents has been confirmed independently. Thus, rigosertib kills cancer cells by destabilizing microtubules, in agreement with our original findings.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sulfonas
/
Tubulina (Proteína)
/
Preparações Farmacêuticas
/
Proliferação de Células
/
Glicina
/
Microtúbulos
/
Neoplasias
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article